Graft-Versus-Host Disease Clinical Trials

3 recruiting

Graft-Versus-Host Disease Trials at a Glance

10 actively recruiting trials for graft-versus-host disease are listed on ClinicalTrialsFinder across 6 cities in 6 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Pittsburgh, Boston, and Bethesda. Lead sponsors running graft-versus-host disease studies include Byung-Sik Cho, Deciphera Pharmaceuticals, LLC, and Anhui Provincial Hospital.

Browse graft-versus-host disease trials by phase

Treatments under study

About Graft-Versus-Host Disease Clinical Trials

Looking for clinical trials for Graft-Versus-Host Disease? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Graft-Versus-Host Disease trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Graft-Versus-Host Disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting

Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives

Graft-Versus-Host DiseaseGraft-versus-leukemiaDonor Apheresis
National Heart, Lung, and Blood Institute (NHLBI)500 enrolled1 locationNCT00001529
Recruiting
Phase 2

A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant

Graft-Versus-Host Disease
Memorial Sloan Kettering Cancer Center44 enrolled9 locationsNCT05675930
Recruiting
Not Applicable

A Trial to Evaluate the Safety and Preliminary Efficacy of iMesenchymal Stromal Cells(iMSC) in Subjects With SR-aGVHD

Steroid-refractory Acute Graft-versus-host Disease(SR-aGVHD)
Anhui Provincial Hospital12 enrolled1 locationNCT06321198
Recruiting

Psychiatric Status and Symptom Severity in Graft-versus-Host Disease (GvHD).

GVHD, ChronicGVHD - Graft-Versus-Host Disease
Medical University of Gdansk200 enrolled1 locationNCT07314892
Recruiting
Phase 2

A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)

Chronic Graft-Versus-Host Disease (cGVHD)
Deciphera Pharmaceuticals, LLC48 enrolled26 locationsNCT06619561
Recruiting
Not Applicable

Electrostimulation Study for Ocular Graft vs. Host Disease

Chronic Ocular Graft-versus-host Disease
Zhonghui K. Luo, MD, PhD15 enrolled1 locationNCT07166848
Recruiting
Phase 2

Comparing the Therapeutic Effects of Using Ruxolitinib and Steroids Concurrently to Steroids Alone as Initial Treatment In Patients Diagnosed With Chronic Graft-versus-host Disease at a Grade of Moderate or Higher Severity

NeoplasmsGVHD - Graft-Versus-Host DiseaseHaematopoietic Stem Cell Transplantation
Byung-Sik Cho88 enrolled1 locationNCT06756061
Recruiting

Cell Free DNA Profiling As a Tool to Monitor Clinically-Relevant Events in Allogeneic Hematopoietic Stem Cell Transplantation

GVHD - Graft-Versus-Host DiseaseInfections After HSCTTransplant Associated Microangiopathy TAM+2 more
University of Turin, Italy30 enrolled2 locationsNCT06715046
Recruiting
Not Applicable

Prospective Clinical Trial for Children With TCRαβ Depleted vs Traditional Haplo Identicle HSCT

Child, OnlyHaploidentical Hematopoietic Stem Cell TransplantationGraft-Versus-Host Disease+1 more
Sijia Gu110 enrolled1 locationNCT06423131
Recruiting
Phase 2

A pilot study of combining rituximab and low-dose (1.0Gy) total nodal irradiation in treatment of extensive chronic graft-versus-host disease

Chronic graft-versus-host disease (GVHD)
Simon He and Andrew Grigg20 enrolled1 locationACTRN12607000628448